News

The on-going European phase III clinical trial will investigate the safety and efficacy of Alzhemed in treating Alzheimer’s disease, with some 930 patients with mild-to-moderate forms of the

CCX915 is a small molecule inhibitor of the CCR2 chemokine receptor which is implicated in the damaging inflammation underlying multiple sclerosis and other autoimmune and inflammatory diseases. “Highly

Using a nuclear magnetic resonance technique, University of Illinois at Chicago (UIC) chemists have obtained the first molecular-level images of precursors of bundled fibrils that form the brain

The results of this collaboration may help Abbott’s drug discovery programs develop drugs that are effective for a wider range of patients. Abbott will fund the research under

The Ginkgo biloba extract EGb 761 was tested in a placebo controlled study in 395 outpatients with mild to moderate dementia and neuropsychiatric symptoms such as depressed mood,

This is in spite of the fact that adult HIV infection rates have actually decreased in certain countries and that changes in behavior to prevent infection such as

The lawsuit is in response to an abbreviated new drug application filed by Ranbaxy with the FDA to market a generic version of Nexium in the US prior

The two unnamed pharmaceutical firms manufacture a number of products, including injectables and tablets. Revenues from the two firms to be acquired are expected to be an aggregate

The three-month delay will allow the FDA sufficient time to review an amendment to Somerset’s new drug application (NDA) submitted following the recommendations of the FDA’s psychopharmacologic drug